ICON Announces Details of New Translational Medicine Unit in Manchester
07 Dezembro 2009 - 8:21AM
Business Wire
ICON plc, (NASDAQ:ICLR)(ISIN:IE0005711209), a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced
details of its new translational medicine unit in Manchester, UK.
The unit is the first deliverable from a collaborative agreement
between ICON and the Central Manchester University Hospitals
Foundation (CMFT) to develop purpose-built translational medicine
facilities on the newly-developed Manchester Royal Infirmary (MRI)
campus.
Scheduled to open in April 2010, the new hospital-based unit
will comprise of 34 beds, an on-site GMP pharmacy, a sample
handling laboratory, multiple meeting and admissions rooms and has
contiguous access to the Accident and Emergency department at the
MRI. The unit will also offer Pharmacodynamic study testing suites
that are fully environmentally controlled, which will be used to
further enhance ICON’s market leadership in the development and
validation of Pharmacodynamic models that assist in identifying
efficacy signals in compounds. The development complements ICON’s
investment in new bioanalytical and biomarker laboratory
capabilities in Manchester in 2008.
“We are delighted to be collaborating with a partner who shares
our vision for early-stage clinical development and are proud to be
developing our world class translational medicine facility at the
CMFT campus,” commented Dr. Thomas Frey, President, ICON
Development Solutions. “We have been conducting clinical
pharmacology in Manchester for over 25 years and this new unit will
enable us to continue to develop the region as an international
centre of excellence in translational medicine. The facilities and
the relationships that ICON has established will enable sponsors to
rapidly access the appropriate populations to develop their
drugs.”
CMFT is a member of the Manchester Academic Health Science
Centre (MAHSC) which is one of only five such sites in the UK
designated by the Department of Health. as a centre of excellence
in applying health research and education into healthcare. Through
the collaboration, ICON will share expertise with academic and
medical communities of this network and has access to the
facilities of the other NHS members and the University of
Manchester. ICON is continuing to build on its established links
with key clinical researchers and clinical research networks.
Recent activity includes diabetic, paediatric, dermatology and
cardiovascular studies.
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has about 7,000 employees, operating from 68 locations in 38
countries.
Further information is available at www.iconplc.com
ICON/ICLR-G
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024